These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24112951)

  • 1. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.
    Golor G; Bensen-Kennedy D; Haffner S; Easton R; Jung K; Moises T; Lawo JP; Joch C; Veldman A
    J Thromb Haemost; 2013 Nov; 11(11):1977-85. PubMed ID: 24112951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
    Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
    J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.
    Gorkom BL; Holme PA; Joch C; Rogosch T; Feussner A; McKeand W; Roberts J; van Heerde W
    Hematology; 2020 Dec; 25(1):17-25. PubMed ID: 31852380
    [No Abstract]   [Full Text] [Related]  

  • 4. Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.
    Négrier C
    Thromb Res; 2016 May; 141 Suppl 3():S9-S12. PubMed ID: 27288065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant fusion protein linking factor VIIa with albumin (rVIIa-FP): Tissue distribution in rats.
    Herzog E; Harris S; McEwen A; Henson C; Pragst I; Dickneite G; Schulte S; Zollner S
    Thromb Res; 2014 Aug; 134(2):495-502. PubMed ID: 24958222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa.
    Schulte S
    Thromb Res; 2008; 122 Suppl 4():S14-9. PubMed ID: 18929521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia.
    Mahlangu JN; Coetzee MJ; Laffan M; Windyga J; Yee TT; Schroeder J; Haaning J; Siegel JE; Lemm G
    J Thromb Haemost; 2012 May; 10(5):773-80. PubMed ID: 22353395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
    Metzner HJ; Pipe SW; Weimer T; Schulte S
    Thromb Haemost; 2013 Nov; 110(5):931-9. PubMed ID: 24178510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged in-vivo half-life of factor VIIa by fusion to albumin.
    Weimer T; Wormsbächer W; Kronthaler U; Lang W; Liebing U; Schulte S
    Thromb Haemost; 2008 Apr; 99(4):659-67. PubMed ID: 18392323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects.
    Møss J; Rosholm A; Laurén A
    J Thromb Haemost; 2011 Jul; 9(7):1368-74. PubMed ID: 21575130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
    Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
    J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
    Tiede A; Friedrich U; Stenmo C; Allen G; Giangrande P; Goudemand J; Hay C; Holmström M; Klamroth R; Lethagen S; McKenzie S; Miesbach W; Negrier C; Yuste VJ; Berntorp E
    J Thromb Haemost; 2011 Jun; 9(6):1191-9. PubMed ID: 21489128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.
    Santagostino E; Negrier C; Klamroth R; Tiede A; Pabinger-Fasching I; Voigt C; Jacobs I; Morfini M
    Blood; 2012 Sep; 120(12):2405-11. PubMed ID: 22859609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.
    Ljung R; Karim FA; Saxena K; Suzuki T; Arkhammar P; Rosholm A; Giangrande P;
    J Thromb Haemost; 2013 Jul; 11(7):1260-8. PubMed ID: 23578227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.
    Salas J; Liu T; Lu Q; Kulman JD; Ashworth T; Kistanova E; Moore N; Pierce GF; Jiang H; Peters R
    Thromb Res; 2015 May; 135(5):970-6. PubMed ID: 25721936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities.
    Shibeko AM; Woodle SA; Mahmood I; Jain N; Ovanesov MV
    J Thromb Haemost; 2014 Aug; 12(8):1302-12. PubMed ID: 24913469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.